Research Paper Volume 15, Issue 13 pp 6503—6525

Figure 3. Loss of Galectin-1 overcomes sorafenib sensitivity and promotes ferroptosis in HCC cells. (A, B) Stable Galectin-1-silenced Huh-7/SR (Huh-7/SR/shGal#23 and #24) and control (Huh-7/SR/shCtrl) cells were analyzed using Western blotting and qRT-PCR. (C) Sorafenib sensitivity in indicated cells analyzed for 48 and 72 h by using the MTT assay. (D) qRT-PCR and Western blotting were used to determine the expression of cancer stem cells markers (Oct-4, Nanog, SOX-2, and KLF4). (E) Western blotting analysis of Galectin-1, GPX4, and FTH-1 expression in Galectin-1-knockdown sorafenib-resistant HCC cells, cells treated with sorafenib (10 μM) for 48 h, and cells not treated with sorafenib, respectively. (F) Lipid peroxidation determined using the MDA assay. Data are presented as means ± standard deviations. *P < 0.05 and **P < 0.01 for Huh-7; #P < 0.05, ##P < 0.01, and ###P < 0.001 for Huh-7/SR/shCtrl (Student’s t test).